CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
COMPUGEN LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026
$1.97+0.01 (+0.51%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 5.2
- Dividend yield
- –
Share price
+$0.09 (+5.07%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
COMPUGEN LTD grew revenue 161.1% to $72.76M over fiscal 2025. Free cash flow was $31.33M, down 36.7% from a year earlier.
Revenue
$72.76M
+161.1% vs. a year earlier
Operating income
$31.33M
FY2025
Free cash flow
$31.33M
-36.7% vs. a year earlier
EPS, diluted
$0.38
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- 5.2
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $72.76M
- Net income
- $35.34M
- EPS, diluted
- $0.38
- Free cash flow
- $31.33M
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
$72.76M+161.1% YoY
Gross profit
$63.51M+218.6% YoY
Operating income
$31.33M
Net income
$35.34M
EPS, diluted
$0.38
Free cash flow
$31.33M-36.7% YoY
Reported period